Copiktra (duvelisib; Verastem/Yakult Honsha) Overview Report 2019: A Highly Selective Small Molecule Inhibitor of the p110-Delta and p110-Gamma Isoforms of the Phosphoinositide 3-Kinase (PI3K) Enzyme - ResearchAndMarkets.com

DUBLIN--()--The "Copiktra" report has been added to ResearchAndMarkets.com's offering.

Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme. The PI3K-delta and PI3K-gamma enzymes are preferentially expressed in leukocytes, where they are responsible for the regulation of cell proliferation, cell migration, and cell activation. The inhibitory function of Copiktra blocks the growth and survival of malignant B cells.

Analyst Outlook

Copiktra (duvelisib; Verastem/Yakult Honsha) is a small molecule inhibitor targeting the phosphoinositide 3-kinase (PI3K) enzyme approved for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) after at least two prior therapies. Results from the Phase III DUO trial revealed that heavily pretreated patients treated with Copiktra exhibited superior median progression-free survival (PFS) versus treatment with Arzerra (ofatumumab; Genmab/Novartis).

Notably, patients with 17p deletion (del17p) CLL also exhibited responses to Copiktra. The presence of del17p is the strongest adverse prognostic factor for survival in CLL patients, and patients with this chromosomal abnormality remain an area of high unmet need. Ongoing Copiktra clinical trials continue to investigate the drug's safety and efficacy in relapsed/refractory CLL, and several early-phase trials suggest that Verastem is looking to target the first-line setting

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Copiktra: Chronic lymphocytic leukemia (CLL)

Copiktra: NHL: Follicular lymphoma (FL)

LIST OF FIGURES

Figure 1: The authors drug assessment summary of Copiktra for CLL

Figure 2: Copiktra sales for CLL across the US, Japan, and five major EU markets, by country, 2017-26

Figure 3: Copiktra for follicular lymphoma - SWOT analysis

Figure 4: The authors drug assessment summary of Copiktra for follicular lymphoma

Figure 5: Copiktra sales for follicular lymphoma across the US and five major EU markets, by country, 2017-26

LIST OF TABLES

Table 1: Copiktra drug profile

Table 2: Approval history of Copiktra for CLL in the US, Japan, and five major EU markets

Table 3: Trials of Copiktra for CLL

Table 4: Copiktra for CLL - SWOT analysis

Table 5: Copiktra drug profile

Table 6: Copiktra pivotal trial data in follicular lymphoma

Table 7: Copiktra sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/a7lwno

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs